CXCL3 is a potential target for breast cancer metastasis

Amanda Lay Pin See, Poh Kuan Chong, Ssu-Yi Lu

  • 1Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, MD6, Centre for Translational Medicine #10-01M, 14 Medical Drive, Singapore 117599. bchlyp@nus.edu.sg.

Insights

Chemokine CXCL3 is upregulated in aggressive breast cancer cells, driving metastasis. Targeting CXCL3 presents a promising therapeutic strategy for breast cancer treatment.

Area of Science:

  • Oncology
  • Proteomics
  • Molecular Biology

Background:

  • Secreted proteins are crucial targets for cancer drug development.
  • Understanding proteins involved in cancer metastasis is key to effective treatment.

Purpose of the Study:

  • To identify and characterize novel secreted protein targets in breast cancer metastasis.
  • To investigate the role of CXCL3 in the progression and metastasis of breast cancer.

Main Methods:

  • Utilized iTRAQ-based tandem mass spectrometry to quantify proteins in breast cancer cell secretomes.
  • Employed siRNA and antibody neutralization assays to study CXCL3 function.
  • Conducted a meta-analysis of CXCL3 mRNA levels in clinical breast cancer samples.

Main Results:

  • CXCL3 was significantly upregulated in highly metastatic breast cancer cell lines.
  • CXCL3 inhibition reduced metastatic potential in vitro.
  • Elevated CXCL3 mRNA levels correlated with clinical breast cancer progression.

Conclusions:

  • CXCL3 plays a functional role in breast cancer metastasis.
  • CXCL3 is a potential therapeutic target for combating breast cancer spread.